Titre:
  • Benefit to neoadjuvant anti-human epidermal growth factor receptor 2 (HER2)-targeted therapies in HER2-positive primary breast cancer is independent of phosphatase and tensin homolog deleted from chromosome 10 (PTEN) status
Auteur:Nuciforo, Paolo Giovanni; Aura, Claudia Monica; Holmes, Eileen; Prudkin, Ludmila; Molina Jimenez, José; Martinez Aznar, Pablo; Ameels, Hélène; de la Peña, Lorena; Ellis, Catherine; Eidtmann, Holger; Piccart-Gebhart, Martine; Scaltriti., Maurizio; Baselga, José
Informations sur la publication:Annals of oncology, 26, 7, page (1494-1500)
Statut de publication:Publié, 2015-07
Sujet CREF:Hématologie
Cancérologie
Mots-clés:Breast cancer
HER2-positive
Lapatinib
PIK3CA
PTEN
Trastuzumab
Note générale:SCOPUS: ar.j
Langue:Anglais
Identificateurs:urn:issn:0923-7534
info:doi/10.1093/annonc/mdv175
info:scp/84940187385